We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 20, 2019

Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or With Nivolumab for Advanced Solid Tumors

JAMA Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Oncology
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial
JAMA Oncol 2019 Nov 07;[EPub Ahead of Print], KM Heinhuis, M Carlino, M Joerger, M Di Nicola, T Meniawy, S Rottey, V Moreno, A Gazzah, JP Delord, L Paz-Ares, C Britschgi, RJ Schilder, K O'Byrne, G Curigliano, E Romano, P Patah, R Wang, Y Liu, G Bajaj, LL Siu

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading